Comparing of Benitec Biopharma Limited (BNTC) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB)

We will be comparing the differences between Benitec Biopharma Limited (NASDAQ:BNTC) and AmpliPhi Biosciences Corporation (NYSEAMERICAN:APHB) as far as institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Benitec Biopharma Limited N/A 0.00 N/A -0.82 0.00
AmpliPhi Biosciences Corporation N/A 532.85 10.14M -0.76 0.00

Table 1 showcases the gross revenue, earnings per share and valuation of Benitec Biopharma Limited and AmpliPhi Biosciences Corporation.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Benitec Biopharma Limited 0.00% 0% 0%
AmpliPhi Biosciences Corporation 0.00% -118.6% -84.7%

Insider and Institutional Ownership

Benitec Biopharma Limited and AmpliPhi Biosciences Corporation has shares owned by institutional investors as follows: 4.11% and 6.5%. Insiders Competitively, owned 1.28% of AmpliPhi Biosciences Corporation shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Benitec Biopharma Limited 32.73% 44.42% -9.25% -22.06% -33.96% 46%
AmpliPhi Biosciences Corporation 4.29% 4.9% 17.35% -72.88% -80.15% 30.83%

For the past year Benitec Biopharma Limited’s stock price has bigger growth than AmpliPhi Biosciences Corporation.


Benitec Biopharma Limited beats AmpliPhi Biosciences Corporation on 4 of the 7 factors.

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology. The company was founded in 1995 and is headquartered in North Sydney, Australia.

AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. It is also developing targeted and personalized bacteriophage therapies for patients with serious or life-threatening antibiotic-resistant infections. The company has reported results from two Phase I clinical trials of AB-SA01 for the treatment of Staphylococcus aureus in chronic rhinosinusitis patients, as well as evaluating the safety of AB-SA01 when administered topically to the intact skin of healthy adults. Its pipeline also includes AB-PA01 for the treatment of pseudomonas aeruginosa lung infections in cystic fibrosis and chronic rhinosinusitis patients. AmpliPhi Biosciences Corporation has a research collaboration agreement with Royal Brompton Hospital; a license agreement with University of Leicester to develop a phage therapy that targets and kills various clinically relevant toxin types of C. difficile; a cooperative research and development agreement with the U.S. Army Medical Research and Materiel Command and the Walter Reed Army Institute of Research to develop and commercialize bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and a clinical trial agreement with the University of Adelaide. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.